（1）Dual mechanism of action to achieve tumor killing: T601 has both the oncolytic mechanism and the targeted chemotherapy mechanism, which can selectively lyse tumor cells and convert 5-FC into 5-FU and 5-FUMP to play the role of targeted chemotherapy;
（2）Enhanced tumor selectivity: T601 is a recombinant oncolytic virus with double-gene knockout of TK and RR, and has better tumor selectivity than oncolytic virus with single-gene knock out of TK;
（3）Reducing the toxic side effects of chemotherapy: Compared with traditional chemotherapy, T601 has high affinity to tumor cells and achieve targeted chemotherapy, which reduces its toxicity to non-tumor tissues;
（4）Rapid progress in R&D: The international development of T601 is advancing smoothly, which will facilitate the progress of the clinical trial in China. Specifically, Transgene is conducting a Phase I/II clinical study on gastrointestinal stromal tumors for TG6002—a counterpart of T601—in France, Italy, Spain and the UK, and part of the Phase I study results will be published in the third quarter of 2020. In the meanwhile, Transgene is also conducting a Phase I/II clinical study on colorectal liver metastase in the UK, and the dosing for the first enrolled subject was completed in February 2020; Furthermore, Transgene is also conducting a clinical study on brain gliomas in France, and this clinical trial is currently ongoing.